Statins inhibit Rho kinase activity in patients with atherosclerosis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background In addition to inhibiting cholesterol synthesis, statins (HMG-CoA reductase inhibitors) decrease the formation of isoprenoid intermediates required for the activation of key signaling pathways, including Rho/Rho kinase (ROCK). In experimental settings, statins inhibit ROCK and reverse vascular dysfunctions in atherosclerosis, independent of cholesterol reduction. It is not known whether statins inhibit ROCK activity in humans with atherosclerosis. Methods We investigated 35 patients with stable atherosclerosis in a randomized, double-blind study comparing treatment with high-dose (80 mg/d) or low-dose (10 mg/d) atorvastatin to placebo for 28 days. Blood samples for leukocyte ROCK activity, fasting lipids, and high-sensitivity C-reactive protein (hs-CRP) were obtained on days 0, 7, 14, and 28 after randomization and change over time with the 2 statin treatments relative to placebo was examined. Results Atorvastatin 80 mg/d reduced ROCK activity (p=0.002 vs. placebo). This decline was rapid and significant within 2 weeks of treatment. The inhibition of ROCK by atorvastatin (80 mg/d) remained significant even after controlling for changes in low-density lipoprotein cholesterol (LDL-C) and triglycerides (p=0.01). Furthermore, there was no correlation between changes in ROCK activity and changes in LDL-C (r=0.2, p=0.25) or triglycerides (r=0.1, p=0.55). There was a modest correlation between ROCK inhibition and change in hs-CRP among patients randomized to atorvastatin 80 mg/d (r=0.6, p=0.07). Conclusions These first-in-man findings demonstrate that high-dose atorvastatin rapidly inhibits the pro-atherogenic Rho/ROCK pathway, independent of cholesterol reduction. This inhibition may contribute to the clinical benefits of statins. Rho/ROCK may provide a useful therapeutic target in patients with atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 1×
“Although not conclusive, these results support the hypothesis that Rho/ROCK inhibition mediates the anti-inflammatory effects of statins and potentially explains the clinical benefit observed in the JUPITER study in patients with elevated CRP levels treated with intensive statin therapy [13].”
ResultRegulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394 · cited 2×
“Mevalonate is also essential for the formation of isoprenoid intermediates such as farnesylpyrophosphate and geranylgeranylpyrophosphate [1].”
BackgroundIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Self-citationPost-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase
Laufs, U., & Liao, J. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.24266 · Cited by 1,035 · cited 1×
“Direct inhibition of Rho or ROCK is anti-atherogenic by augmenting endothelial nitric oxide synthesis [16], decreasing vascular smooth muscle cell contraction and proliferation [17], decreasing cytokine formation and inflammatory cell trafficking and proliferation [18,19], and reducing thrombogenicity of the vessel wa…”
BackgroundSelf-citation
Cited by
Pleiotropic Effects of Statins on the Cardiovascular System
Oesterle, A., Laufs, U., & Liao, J. K. (2017) · Circulation Research · doi:10.1161/circresaha.116.308537 · Cited by 1,247
Self-citationFlow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis
Wang, K.-C., Yeh, Y.-T., Nguyen, P., Limqueco, E., Lopez, J., Thorossian, S., Guan, K.-L., Li, Y.-S. J., & Chien, S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613121113 · Cited by 471
Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension
Tanna, A. P., & Johnson, M. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.04.040 · Cited by 257
Knipe, R. S., Tager, A. M., & Liao, J. K. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009381 · Cited by 233
Self-citationBerwanger, O., Santucci, E. V., de Barros e Silva, P. G. M., Jesuíno, I. D. A., Damiani, L. P., Barbosa, L. M., Santos, R. H. N., Laranjeira, L. N., Egydio, F. D. M., Borges de Oliveira, J. A., et al. (2018) · JAMA · doi:10.1001/jama.2018.2444 · Cited by 131
Metadata
- Authors
- Nohria, A., Prsic, A., Liu, P.-Y., Okamoto, R., Creager, M. A., Selwyn, A., Liao, J. K., & Ganz, P.
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2009-08
- Volume
- 205
- Issue
- 2
- Pages
- 517-521
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W2092042066
- Cited by
- 143
- References
- 7
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statins inhibit Rho kinase activity in patients with atherosclerosis. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2008.12.023
- The paper
- Nohria, A., Prsic, A., Liu, P.-Y., Okamoto, R., Creager, M. A., Selwyn, A., Liao, J. K., & Ganz, P. (2009). Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2008.12.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.